gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'- reactive, tumoricidal T cells using high-affinity, altered peptide ligand

Willem W. Overwijk, Allan Tsung, Kari R. Irvine, Maria R. Parkhurst, Theresa J. Goletz, Kangla Tsung, Miles W. Carroll, Chunlei Liu, Bernard Moss, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticlepeer-review


Many tumor-associated antigens are nonmutated, poorly immunogenic tissue differentiation antigens. Their weak immunogenicity may be due to 'self'- tolerance. To induce autoreactive T cells, we studied immune responses to gp100/pmel 17, an antigen naturally expressed by both normal melanocytes and melanoma cells. Although a recombinant vaccinia virus (rVV) encoding the mouse homologue of gp100 was nonimmunogenic, immunization of normal C57BL/6 mice with the rVV encoding the human gp100 elicited a specific CD8+ T cell response. These lymphocytes were cross-reactive with mgp100 in vitro and treated established B16 melanoma upon adoptive transfer. To understand the mechanism of the greater immunogenicity of the human version of gp100, we characterized a 9-amino acid (AA) epitope, restricted by H-2Db, that was recognized by the T cells. The ability to induce specific T cells with human but not mouse gp100 resulted from differences within the major histocompatibility complex (MHC) class I restricted epitope and not from differences elsewhere in the molecule, as was evidenced by experiments in which mice were immunized with rVV containing minigenes encoding these epitopes. Although the human (hgp10025-33) and mouse (mgp10025-33) epitopes were homologous, differences in the three NH2-terminal AAs resulted in a 2-log increase in the ability of the human peptide to stabilize 'empty' Db on RMA-S cells and a 3-log increase in its ability to trigger interferon γ release by T cells. Thus, the fortuitous existence of a peptide homologue with significantly greater avidity for MHC class I resulted in the generation of self-reactive T cells. High-affinity, altered peptide ligands might be useful in the rational design of recombinant and synthetic vaccines that target tissue differentiation antigens expressed by tumors.

Original languageEnglish (US)
Pages (from-to)277-286
Number of pages10
JournalJournal of Experimental Medicine
Issue number2
StatePublished - Jul 20 1998


  • CD8 T lymphocyte
  • Gp100
  • Melanoma
  • Tumor-associated antigen
  • Xenoimmunization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'- reactive, tumoricidal T cells using high-affinity, altered peptide ligand'. Together they form a unique fingerprint.

Cite this